Navigation Links
Aspirin intake may stop growth of vestibular schwannomas/acoustic neuromas
Date:1/23/2014

BOSTON (Jan. 24, 2014) Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated, for the first time, that aspirin intake correlates with halted growth of vestibular schwannomas (also known as acoustic neuromas), a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

Motivated by experiments in the Molecular Neurotology Laboratory at Mass. Eye and Ear involving human tumor specimens, the researchers performed a retrospective analysis of over 600 people diagnosed with vestibular schwannoma at Mass. Eye and Ear. Their research suggests the potential therapeutic role of aspirin in inhibiting tumor growth and motivates a clinical prospective study to assess efficacy of this well-tolerated anti-inflammatory medication in preventing growth of these intracranial tumors.

"Currently, there are no FDA-approved drug therapies to treat these tumors, which are the most common tumors of the cerebellopontine angle and the fourth most common intracranial tumors," explains Konstantina Stankovic, M.D., Ph.D., Mass. Eye and Ear clinican-researcher and assistant professor of otology andlaryngology, Harvard Medical School, who led the study. "Current options for management of growing vestibular schwannomas include surgery (via craniotomy) or radiation therapy, both of which are associated with potentially serious complications."

The findings, which are described in the February issue of the journal Otology and Neurotology, were based on a retrospective series of 689 people, 347 of whom were followed with multiple magnetic resonance imaging MRI scans (50.3%). The main outcome measures were patient use of aspirin and rate of vestibular schwannoma growth measured by changes in the largest tumor dimension as noted on serial MRIs. A significant inverse association was found among aspirin users and vestibular schwannoma growth (odds ratio: 0.50, 95 percent confidence interval: 0.29-0.85), which was not confounded by age or gender.

"Our results suggest a potential therapeutic role of aspirin in inhibiting vestibular schwannoma growth," said Dr. Stankovic, who is an otologic surgeon and researcher at Mass. Eye and Ear, Assistant Professor of Otology and Laryngology, Harvard Medical School (HMS), and member of the faculty of Harvard's Program in Speech and Hearing Bioscience and Technology.


'/>"/>

Contact: Mary Leach
Mary_Leach@meei.harvard.edu
617-573-4170
Massachusetts Eye and Ear Infirmary
Source:Eurekalert

Related biology news :

1. A new form of aspirin to overcome aspirin resistance
2. Research shows how aspirin may act on blood platelets to improve survival in colon cancer patients
3. Modest alcohol intake associated with less inflammation in patients with common liver disease
4. Red potato chips: Segmentation cues can substantially decrease food intake
5. Fast food restaurant lighting and music can reduce calorie intake and increase satisfaction
6. Omega-3 intake heightens working memory in healthy young adults
7. Research provides new insights into dogs natural feeding behavior and finds they target a daily dietary intake that is high in fat
8. New health-economic model shows benefits of boosting dietary calcium intake
9. Community-based nutrition education shown to be successful in increasing calcium intake
10. Cats are able to navigate complex combinations of wet and dry foods to achieve a consistent intake of protein, fat and carbohydrate
11. New study sheds light on link between dairy intake and bone health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a Chicago-based ... recent FDA Class II 510(k) clearance for their flagship medical device, SimplECG. , ... cardiac monitoring devices that rely on cloth-based nanosensors. While other companies have attempted ...
(Date:12/2/2016)... 1, 2016   SurePure, Inc. (OTCQB: SURP) ... the Company has concluded an agreement with Tamarack Biotics ... 90-day period to acquire units of the Company,s patented ... 3.7 million.  Concurrently with the option, ... which Tamarack will seek regulatory approvals in ...
(Date:11/30/2016)... ... 2016 , ... BEI Kimco, a brand of Sensata Technologies, ... that ensures high alignment accuracy by preventing unwanted shaft rotation. The new VCA ... precision is required, such as in medical equipment, laboratory instrumentation, clean rooms, low-outgassing ...
Breaking Biology Technology: